Business Support Consultancy Panel DPS

Complete

Value

£165,000

Classifications

  • Business and management consultancy services
  • Project management consultancy services

Tags

  • tender

Submission Deadline

8 months ago

Published

1 year ago

Description

The proposed programme of support (1:1 and 1:many) funded via the UK Shared Prosperity Fund and the Department of Business, Innovation and Skills, will continue to build on the work of 3 successful BEIS funded 121 programmes and past ‘Growth Hub Guru’ workshop programmes.It is the Council’s intention to establish a panel of consultants who will deliver 121 specialist support to a wide range of trading businesses from new start ups through to those with growth aspirations.The scheme will run from mid June 2023 to complete by March 2025The 1:1 consultancy support will be fully funded to participating SME businesses and will aim to support businesses with the delivery of their aspirations through practical support. However, there will be two other support focuses namely increasing business resilience and to support productivity improvements.

Similar Contracts

Open

Provision and Implementation of an Integrated HR, Payroll and Finance System

As part of our programme of change, Tai Tarian is seeking to award a Contract to a Supplier for the Provision and Implementation of an Integrated HR, Payroll and Finance System, to improve our colleague experience. The scope of this Contract comprises of the implementation of an integrated HR, Payroll and Finance solution that provides a platform that streamlines people management, payroll processing and financial operations into a single seamless system providing a cohesive user experience. The solution must be cloud-based, scalable, secure, and compliant with UK regulations, including GDPR requirements. It must support automation, enable efficient data management, and provide robust reporting and analytics capabilities. The successful Supplier must demonstrate a strong commitment to delivering a high-quality user interface and user experience. The solution should be intuitive, accessible, and designed with the end user in mind. A detailed Specification of the requirements is provided in Appendix 1 (Functional and Non-functional Specification of Requirements) and Tenderers must complete Appendix 2 (Price Framework) to confirm the whole-life costs to deliver all the requirements of the Contract. The key deliverables of the Contract are: - A robust product development roadmap demonstrating futureproofing and scalability for at least a 5-10 year horizon. - A strong commitment to delivering a high-quality user interface and user experience. The solution should be intuitive, accessible, and designed with the end user in mind. - Improved operational efficiency providing a demonstrable return on investment. - Enhanced employee experience. - Real-time financial visibility. - Mobile and self-service portals/apps. - Real-time dashboards and analytics (e.g. financial performance reports, workforce and payroll dashboards, KPI tracking etc.). - Implementation, Design, configuration, and deployment of HR, Payroll, and Finance modules, including employee lifecycle management, payroll processing, general ledger and purchase ledger features and financial transaction management. - Environment management. - Testing: Test strategy and planning, System Integration Testing (SIT), Functional Acceptance Testing (FAT) and bug fixing throughout (UAT). - Data migration through a Data Warehouse to target solution, API integrations and compliance with UK statutory requirements (e.g., HMRC, pensions, financial reporting). - Training and Documentation: user manuals and quick reference guides, technical documentation for support teams, training materials and delivery and knowledge transfer to internal teams. - Cutover planning and change management support, acceptance into service and post-implementation support including user documentation and helpdesk services. - Licences to use the proposed system. Further information is provided in the Invitation to Tender document.

Katy Reed

Published 6 hours ago
Open

PACE Interim Impact Report

PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community. PACE brings together the funding, resources, and partnerships to help innovators progress their early-stage antimicrobial drug and diagnostics projects with greater speed, support and confidence - giving the best AMR innovations the greatest chance of success. PACE will create a path to value through 3 strategic goals which will be underpinned by effective programme management and delivery: Grow a pipeline of high-quality antimicrobial drugs and associated diagnostics aligned with unmet needs and route to patient impact. Provide innovative researchers in Academia and SMEs located globally the funding, advice and support they need to build de-risked and investment ready assets Convene collaboration network(s) to identify barriers to innovation, advance programmes and drive new collaborative R&D. It is a requirement of MDC's grant funding agreement with Innovate UK and LifeArc that the outcomes and long-term impacts of PACE activities are assessed at key time points throughout the programme's timeline. The PACE programme is funded for an initial term of five years and as of April 2026 will reach its midway point in this funding cycle and so there is a need to conduct an interim review of progress towards expected outcomes. Findings from this interim review will directly inform programme refinement. Key to this will be the opportunity to gather feedback and learning from Round 1 beneficiaries and partners on the PACE Academy, the project management process, and the use of Enabling projects so far. It will also allow the programme to capture the experiences of beneficiaries from Round 2 to date. This will provide learning in how best to support the Round 2 beneficiaries and for the future Round 3 of funding which will be targeted at a second group of therapeutic companies. It is expected that findings from the interim review will directly inform the need and shape for PACE beyond the first 5 - year funded term. The PACE programme is now looking for an external provider to develop and produce an interim impact review and report (that will build upon the existing baseline impact study completed in June 2025) to understand how key activities are progressing towards expected outcomes which can be compared to the findings from the baseline study and at the endline stage. The overall purpose of the impact evaluation and this interim review is to be able to assess the impact of PACE on the AMR drug development ecosystem and on the development of drugs and diagnostics.

Katy Reed

Published 8 hours ago

AI Bid Assistant

Our AI-powered tool to help you create winning bids is coming soon!

View Contract Source Save Contract

Timeline complete